Cullinan Therapeutics, Inc.CGEM
Price (close)
$14.81
Market cap
$953.0M
P/E
—
Revenue (TTM)
—
Net income
-$204.7M
Dividend yield
—
1-year total return
147.2%
Net margin
—
Revenue growth
—
Debt / equity
—
What Cullinan Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $18.9M | $0 | — | — | — |
| Net income | -$51.8M | -$65.6M | $111.2M | -$153.2M | -$167.4M | -$219.9M |
| Free cash flow | -$29.8M | -$43.4M | -$127.8M | -$134.5M | -$145.3M | -$175.8M |
More on CGEM.
- Cullinan Therapeutics, Inc. summary
- Cullinan Therapeutics, Inc. financial statements
- Cullinan Therapeutics, Inc. key metrics
- Cullinan Therapeutics, Inc. health scores and style box
- Cullinan Therapeutics, Inc. earnings
- Cullinan Therapeutics, Inc. dividends
- Cullinan Therapeutics, Inc. valuation
- Cullinan Therapeutics, Inc. ownership and insiders
- Cullinan Therapeutics, Inc. peers
Figures from Cullinan Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.